DONALD YEE to Middle Aged
This is a "connection" page, showing publications DONALD YEE has written about Middle Aged.
Connection Strength
0.033
-
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med. 2026 Apr 09; 394(14):1388-1398.
Score: 0.015
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
Score: 0.014
-
Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4.
Score: 0.005